Literature DB >> 7572623

Effects of pregnancy on first onset and symptoms of paroxysmal supraventricular tachycardia.

S H Lee1, S A Chen, T J Wu, C E Chiang, C C Cheng, C T Tai, C W Chiou, K C Ueng, M S Chang.   

Abstract

It is important for women to understand the risk of first onset and symptomatic exacerbation of paroxysmal supraventricular tachycardia (SVT) during pregnancy. Reports regarding the effects of pregnancy on first onset and symptomatic exacerbation of paroxysmal SVT have been controversial, and have not been conducted in a systematic fashion. Two hundred seven consecutive female patients diagnosed with symptomatic paroxysmal SVT were requested to respond to multiple questionnaires before electrophysiologic study and catheter ablation. A person-years data method was used to estimate risk of first onset of paroxysmal SVT during pregnancy. Exacerbation of paroxysmal SVT was assessed by a score scale including each of the following symptoms: palpitation, fatigue, rest dyspnea, effort dyspnea, dizziness, chest oppression, blurred vision, and syncope (total score change > 2 points). In the 107 patients with accessory pathway-mediated tachycardia, 7 patients had had a first onset of tachycardia during pregnancy (relative risk ratio 0.86, confidence interval 0.4 to 1.9, p = 0.35). In the 100 patients with atrioventricular nodal reentrant tachycardia, 1 patient had had the first onset of tachycardia during pregnancy (relative risk ratio 0.11, confidence interval 0.02 to 0.56, p = 0.004). Otherwise, 14 of the 63 patients (22%) with tachycardia in the pregnant and nonpregnant periods had exacerbation of symptoms during pregnancy. Thus, first onset of paroxysmal SVT during pregnancy was rare (3.9%), and pregnancy was associated with a low risk of first onset of paroxysmal SVT. However, symptoms of paroxysmal SVT were exacerbated during pregnancy in some patients.

Entities:  

Mesh:

Year:  1995        PMID: 7572623     DOI: 10.1016/s0002-9149(99)80195-7

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  14 in total

1.  Harnessing the Power of Pregnancy and Pregnancy-Related Events to Predict Cardiovascular Disease in Women.

Authors:  Monika Sanghavi; Nisha I Parikh
Journal:  Circulation       Date:  2017-02-07       Impact factor: 29.690

2.  A hormonal FBI.

Authors:  J M van Opstal; C R Hoorntje; L M Rodriguez
Journal:  Neth Heart J       Date:  2004-09       Impact factor: 2.380

3.  Pharmacological Therapy of Tachyarrhythmias During Pregnancy.

Authors:  Ameeta Yaksh; Lisette Jme van der Does; Eva Ah Lanters; Natasja Ms de Groot
Journal:  Arrhythm Electrophysiol Rev       Date:  2016-05

Review 4.  Maternal cardiac arrhythmias during pregnancy and lactation.

Authors:  Rachael Cordina; Mark A McGuire
Journal:  Obstet Med       Date:  2010-03-04

Review 5.  Management of tachyarrhythmias in pregnancy - A review.

Authors:  Priyanka Kugamoorthy; Danna A Spears
Journal:  Obstet Med       Date:  2020-04-20

6.  Population pharmacokinetics, tolerability, and safety of dihydroartemisinin-piperaquine and sulfadoxine-pyrimethamine-piperaquine in pregnant and nonpregnant Papua New Guinean women.

Authors:  John M Benjamin; Brioni R Moore; Sam Salman; Madhu Page-Sharp; Somoyang Tawat; Gumal Yadi; Lina Lorry; Peter M Siba; Kevin T Batty; Leanne J Robinson; Ivo Mueller; Timothy M E Davis
Journal:  Antimicrob Agents Chemother       Date:  2015-05-11       Impact factor: 5.191

7.  Cardiac arrhythmias during pregnancy.

Authors:  Thomas Adam Burkart; Jamie Beth Conti
Journal:  Curr Treat Options Cardiovasc Med       Date:  2010-10

Review 8.  Gender and cardiac arrhythmias.

Authors:  R P Villareal; A L Woodruff; A Massumi
Journal:  Tex Heart Inst J       Date:  2001

9.  Emergency therapy of maternal and fetal arrhythmias during pregnancy.

Authors:  Hans-Joachim Trappe
Journal:  J Emerg Trauma Shock       Date:  2010-04

Review 10.  Arrhythmias in the pregnant patient: current concepts in evaluation and management.

Authors:  Jordana Kron; Jamie B Conti
Journal:  J Interv Card Electrophysiol       Date:  2007-08-09       Impact factor: 1.900

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.